^
Association details:
| Biomarker: | MTAP mutation |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Published date:
04/14/2022
Excerpt:
The ALPHA study (NCT03695510) was a single-arm, Phase II study with Simon's 2-stage design. Afatinib and pembrolizumab were administered to patients with platinum-refractory, recurrent, or metastatic HNSCC....EGFR amplification predicted a higher response rate (EGFR amplification, n = 3; ORR, 100%, Fisher exact test, P = 0.07). Methylthioadenosine phosphorylase (MTAP) loss or mutation predicted a lower response rate (MTAP loss or mutation, n = 5; ORR, 0%, Fisher exact test, P = 0.046)....Afatinib may augment pembrolizumab therapy and improve the ORR in patients with HNSCC.
DOI:
10.1158/1078-0432.CCR-21-3025
